# Can ARA-290 provide neuroprotection against ischemic brain damage?

Canonical source: https://retacompare.com/research/can-ara-290-provide-neuroprotection-against-ischemic-brain-damage

Peptide Longevity Q&A · 2017-08-17


    Research indicates that ARA-290, a peptide derived from erythropoietin (EPO), may offer neuroprotective effects against ischemic brain damage. In animal models, ARA-290 demonstrated significant reduction in brain injury and improved mitochondrial function compared to EPO, suggesting its potential therapeutic role in neurodegenerative conditions.

 What the research shows

The study examined the neuroprotective effects of a novel erythropoietin-derived peptide, MK-X, which is related to ARA-290, in a preclinical model of ischemic stroke. Using a mouse model with middle cerebral artery occlusion, researchers assessed brain injury following reperfusion. The results indicated that MK-X administration significantly reduced brain injury compared to EPO. Additionally, MK-X effectively ameliorated mitochondrial dysfunction and neuronal death induced by glutamate-induced oxidative stress in cultured neurons. The study also reported that MK-X mimicked EPO's activation of critical signaling pathways, including JAK2, PI3K/AKT, and ERK1/2, which are involved in neuroprotection.

 Why it matters for longevity

The findings of this research are particularly relevant to longevity and age-related neurodegenerative diseases. As the population ages, the incidence of conditions such as ischemic stroke increases, leading to significant morbidity and mortality. ARA-290, through its neuroprotective properties, could potentially mitigate some of the neurological decline associated with aging. By improving mitochondrial function and reducing neuronal death, ARA-290 may help maintain cognitive function and overall brain health in older adults.

 Key findings at a glance

ARA-290, derived from EPO, was tested for neuroprotective effects.

In mouse models, ARA-290 significantly reduced brain injury from ischemic stroke.

ARA-290 improved mitochondrial function and reduced neuronal death due to oxidative stress.

Both ARA-290 and EPO activated similar neuroprotective signaling pathways.

ARA-290 penetrated the brain more effectively than EPO.

 How ARA-290 works (background)

ARA-290 functions by mimicking the effects of erythropoietin, a cytokine known for its role in red blood cell production. However, its neuroprotective effects extend beyond hematopoiesis. ARA-290 engages signaling pathways such as JAK2 and PI3K/AKT, which are crucial for cell survival and function. By enhancing these pathways, ARA-290 may protect neurons from excitotoxicity and oxidative stress, common contributors to neurodegeneration. The ability of ARA-290 to cross the blood-brain barrier more effectively than EPO further enhances its potential as a therapeutic agent in neuroprotection.

 Safety, caveats, and what we don't yet know

While the research shows promising results for ARA-290 in preclinical models, it is essential to note that these findings are preliminary. The study primarily involved animal models, and further research is necessary to evaluate the safety and efficacy of ARA-290 in human populations. Additionally, the long-term effects and potential side effects of ARA-290 have not been fully explored. Understanding these factors will be crucial for its development as a therapeutic option for neuroprotection in aging individuals.

 Bottom line

ARA-290 shows potential as a neuroprotective agent against ischemic brain damage, with promising results in preclinical models. Its ability to improve mitochondrial function and reduce neuronal death highlights its relevance for aging and neurodegenerative diseases.

 Related questions

 Does ARA-290 improve cognitive function in aging populations?

Research suggests that ARA-290 may enhance cognitive function by protecting neurons from oxidative stress and excitotoxicity, although further studies in human populations are required to confirm these effects.

 What are the potential side effects of ARA-290?

While ARA-290 shows promise in neuroprotection, its safety profile in humans is not yet fully established, necessitating further research to identify any potential side effects or long-term implications.

 How does ARA-290 compare to traditional neuroprotective therapies?

ARA-290 may offer advantages over traditional neuroprotective therapies by providing similar protective effects without the adverse side effects associated with erythropoietin, particularly concerning erythropoiesis and tumor growth.

 Source: PubMed · Cell Death Dis · published 2017-08-17.

## Sources

- PubMed · Cell Death Dis: https://pubmed.ncbi.nlm.nih.gov/28817120/